Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Brant RF; International Society of Technology Assessment in Health Care. Meeting.

Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 1995; 11: Abstract No. 209.

University of Calgary, Alberta, Canada.

Deep vein thrombosis (DVT) is a potentially life-threatening complication of hip implant (HIP) surgery. We have performed a double-blind randomized trial comparing the effectiveness and safety of warfarin sodium (WARF) with low-molecular-weight heparin (LMWH) in DVT prophylaxis in HIP patients. We report the outcomes obtained using a standardized prescriptive protocol to adjust WARF according to the Internationalized Normal Ratio (INR) (therapeutic range 2.0-3.0) and according to a predefined WARF nomogram: INR < 1.3, Warfarin Dose 10.0 mg; INR 1.4 to 1.8, Warfarin Dose 7.5 mg; INR 1.9 to 2.3, Warfarin Dose 5.0 mg; INR 2.4 to 2.8, Warfarin Dose 2.5 mg; INR > 2.8, Warfarin Dose 0.0 mg. The INR was performed daily, and the daily WARF dose was determined by the WARF nomogram. Among the 665 patients (83.6%) of the 795 HIP patients with interpretable venograms, 79 of 340 patients (23.2%) in the WARF group and 69 of 332 patients (20.8%) in the LMWH group had DVT. Major bleeding occurred in 6 (1.5%) of patients in the WARF group compared with 11 (2.8%) in the LMWH group. Our findings demonstrate that WARF administered according to the nomogram provides effective and safe prophylaxis.

Publication Types:

• Meeting Abstracts

Keywords:

• Arthroplasty, Replacement, Hip
• Blood Coagulation Factors
• Double-Blind Method
• Hemorrhage
• Heparin, Low-Molecular-Weight
• Hip Prosthesis
• Humans
• International Normalized Ratio
• Phlebography
• RPL29 protein, human
• Thrombophlebitis
• Venous Thrombosis
• Warfarin
• prevention & control
• radiography
• surgery
• hsrmtgs

Other ID:

• HTX/96714983

UI: 102215955

From Meeting Abstracts